Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CERAMENT G is a **synthetic, resorbable bone void filler** designed for local application in bone voids or defects, especially during surgical treatment of osteomyelitis and open fractures in skeletally mature patients. It is a combination of hydroxyapatite (40%), calcium sulfate (60%), and gentamicin sulfate (17.5 mg/mL paste), delivered as an injectable or bead-form paste. The calcium sulfate component provides rapid resorption, while hydroxyapatite serves as a slowly resorbable osteoconductive scaffold for new bone formation. Gentamicin is locally eluted, offering high concentrations at the defect site to reduce colonization and recurrence of infection by gentamicin-sensitive microorganisms. Systemic antibiotic therapy is still recommended in conjunction. CERAMENT G is fully remodeled into host bone within 6-12 months after implantation[1][2][3][4][5][6][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CERAMENT G.